EDIT Editas Medicine Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:

  • Guggenheim’s Inaugural Healthcare Innovation Conference

    Format: Fireside Chat

    Date: Tuesday, November 12

    Time: 4:00 p.m. ET

    Location: Boston, MA
  • Stifel 2024 Healthcare Conference

    Format: Fireside Chat

    Date: Tuesday, November 19

    Time: 1:50 p.m. ET

    Location: New York, NY
  • 7th Annual Evercore ISI HealthCONx Conference

    Format: Fireside Chat

    Date: Tuesday, December 3

    Time: 1:20 p.m. ET

    Location: Coral Gables, FL

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at . An archived replay will be available for approximately 30 days following each event.

About Editas Medicine

As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit .



Media and Investor Contact:
Cristi Barnett
(617) 401-0113
EN
06/11/2024

Underlying

EDITEditas Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December: Guggenheim’s Inaugural Healthcare Innovation ConferenceFormat: Fireside ChatDate: Tuesday, November 12Time: 4:00 p.m. ETLocation: Boston, MA Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, November 19Time: 1:50 p.m. ETLocation: New York, NY 7th Annual Ever...

8h / 42m 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Third Quarter 2024 Results and Business Upda...

Editas Medicine Announces Third Quarter 2024 Results and Business Updates Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in v...

November 4, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Progress Towards 2024 Goals, Including Achie...

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Initiated process to partner or out-license reni-cel to focus resources on in vivo pipeline development Company to present data and discuss strategic update in a today at 8:00 a.m. ET CA...

October 22, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel ...

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems...

October 21, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Host Strategic Update Webinar to Detail Progress To...

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. ET to share achievement of in vivo preclinical proof of concept data and business development and financial updates. Webinar Presentatio...

October 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch